---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-018383"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2022-12-06T23:59:59+00:00"
generated_at: "2026-06-21T08:55:49.584888+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Editas reports positive Phase 1/2 RUBY trial data for EDIT-301 in sickle cell disease

## Summary
- First two patients engrafted successfully; no vaso-occlusive events after treatment with EDIT-301.
- Patient 1 at 5 months post-treatment: total hemoglobin 16.4 g/dL, fetal hemoglobin 45.4%, HbF pancellular >95%.
- EDIT-301 well-tolerated; safety profile consistent with myeloablative conditioning and autologous transplant.
- First clinical use of proprietary AsCas12a nuclease to edit human cells; further data expected mid-2023.

## SEC filing metadata
- accession: 0001558370-22-018383
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2022-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000155837022018383/0001558370-22-018383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000155837022018383/edit-20221206x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-018383
- JSON: https://secwatch.observer/filing/0001558370-22-018383.json
- Plain text: https://secwatch.observer/filing/0001558370-22-018383.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.